NEW YORK, May 20-Bruker Daltonics and Matritech said today that they will work together to develop an automated mass spectrometer for proteomics-based clinical cancer diagnostics.
The two companies will partner to adapt Bruker's MALDI-TOF spectrometer technology to perform tests for the early detection of prostate and breast cancer.
The resulting system will be "turn-key," said Matritech COO and president David Corbet in a statement, allowing clinical laboratories to deliver the company's proprietary tests to market quickly.
Financial details were not disclosed.
Matritech, based in Newton, Mass., develops proteomics-based diagnostics for early cancer detection. The company has identified markers associated with breast, bladder, prostate, cervical and colon cancers, and has a bladder cancer test currently on the market. The company is publicly owned.
Bruker Daltonics, based in Billerica, Mass., is a major provider of mass spectrometry and analysis systems.